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Abstract
The mechanisms of successful epigenetic reprogramming in cancer are not well characterized as they involve coordinated
removal of repressive marks and deposition of activating marks by a large number of histone and DNA modification
enzymes. Here, we have used a cross-species functional genomic approach to identify conserved genetic interactions to
improve therapeutic effect of the histone deacetylase inhibitor (HDACi) valproic acid, which increases survival in more than
20% of patients with advanced acute myeloid leukemia (AML). Using a bidirectional synthetic lethality screen revealing
genes that increased or decreased VPA sensitivity in C. elegans, we identified novel conserved sensitizers and synthetic
lethal interactors of VPA. One sensitizer identified as a conserved determinant of therapeutic success of HDACi was UTX
(KDM6A), which demonstrates a functional relationship between protein acetylation and lysine-specific methylation. The
synthetic lethal screen identified resistance programs that compensated for the HDACi-induced global hyper-acetylation,
and confirmed MAPKAPK2, HSP90AA1, HSP90AB1 and ACTB as conserved hubs in a resistance program for HDACi that are
drugable in human AML cell lines. Hence, these resistance hubs represent promising novel targets for refinement of
combinatorial epigenetic anti-cancer therapy.
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Introduction
Epigenetic changes in cancer involve cooperation of multiple
processes including covalent modification of histones, where
histone acetylation and methylation are among the modifications
shown to contribute to epigenetic reprogramming in cancer
[1,2,3]. Histone deacetylase inhibitors (HDACi) have antitumor
potential [4] and represent important therapeutic supplements in
acute myeloid leukemia (AML) [5,6] where the need for effective
low toxic therapy in an elderly patient population is critical [7].
Although current HDACi are criticized for being too unspecific,
they have properties recommending them as therapeutic drugs,
such as low general toxicity and promising effects at low doses.
Moreover, many HDACis show synergy with standard chemo-
therapy [8]. The histone deacetylase class I and II inhibitor
valproic acid (VPA) is an example of a well-tolerated anticonvul-
sant with a safety profile that allows long-term use in children [9].
VPA affects cell growth, differentiation and apoptosis [10,11] and
is well tolerated in combination with chemotherapeutics and
targeted therapy [12,13,14,15,16]. Myelodysplastic syndromes
(MDS) and advanced AML are both diseases where genetic and
epigenetic changes interact to promote initiation and progression
of the cancer phenotype [17]. In approximately 30% of these
patients, VPA induces pronounced cytostatic effects, disease
stabilization and promising hematological responses [13]. Hence,
identification of resistance mechanisms and effective co-therapeu-
tics are important in order to improve VPA-efficacy in the non-
responsive patients.
Epigenetic changes in cancer are global and a large number of
enzymes are known to covalently modify histones and DNA with
varying effects on different genes [1]. Given this complexity, there
is lack of clarity of mechanisms and interrelation between different
types of histone marks and the enzymes that deposit them.
Appropriate functional genomic strategies are well suited to
analyze the global biological end-points of such wide-ranging
responses [17]. As changes in transcription are direct biological
end-points of epigenetic reprogramming we previously identified
gene sets unique for AML cells from VPA resistant patients [14].
The functional and mechanistic relevance of the gene expression
changes were difficult to determine as different processes
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mediating epigenetic regulation of gene expression are intimately
linked and affect a range of biological endpoints. Proteomic
approaches are therefore used to supplement gene expression
analyses and have been successfully implemented in the identifi-
cation of new targets for improvement of conventional chemo-
therapy in AML [18,19,20]. Another approach to identify
appropriate anti-cancer epigenetic switches is genetic interaction-
studies to identify synthetic lethal interactions. Synthetic lethal
interactions may also identify prognostic markers and mechanistic
requirements of drug action.
Caenorhabditis elegans (C. elegans) is a powerful animal model for
assessment of functional roles of genes and pathways [21,22].
Robust RNA interference (RNAi) technology contributes to the
success of C. elegans by allowing synthetic lethality screens to be
performed [23]. RNAi may also provide a highly effective method
for discovery of therapeutic targets in AML [24,25]. Moreover, C.
elegans is an appropriate model to assess functions of VPA-
regulated genes; VPA induces similar responses in C. elegans as in
mammalian cells, including activation of DNA damage response
[26] and developmental arrest.
We hypothesized that use of in vivo models for functional
validation would facilitate the translation of complex datasets into
clinically useful biomarkers and molecular targets for enhance-
ment of VPA-therapy in AML at low cost. A pre-existing human
gene expression dataset of VPA resistance was complemented with
an in vivo rat leukemia phosphoproteomic screen, and synthetic
lethality in C. elegans was exploited as a functional validation tool
(Figure 1). Using this strategy we identified novel conserved
sensitizers and synthetic lethal interactors of VPA, as well as
conserved resistance pathways converging on HSP90AB1,
HSP90AA2, and MAPKAPK2. These observations, together with
a functional relationship between protein acetylation and protein
methylation involving UTX (UTX-1) suggested multiple molec-
ular mechanisms for effective anti-cancer valproic acid therapy.
Materials and Methods
Animals
200–250 g male Brown Norwegian rats (BN/mcwi) (Charles
River Laboratories, Wilmington, MA, USA) were injected
intravenously in the lateral tail vein with 10 million (pulsed
treatment (PT) group) or 5 million (chronic treatment (CT) group)
Brown Norwegian myeloid leukemia (BNML) cells on day 0
respectively. The PT group received VPA (Desitin Pharma AS,
Hamburg, Germany) by intra peritoneal injections (400 mg/kg)
and the CT group by oral gavage (170 mg/kg). The control group
received vehicle only. Treatment was initiated day 10 (PT) or day
16 (CT) increasing the dose on day 17 (170 mg/kg twice daily
(b.i.d.)) for the latter group. Animals were treated until sacrificed at
humane endpoint, defined as loss of 10–15% of body weight in
addition to ataxia, paralysis of hind or fore limbs, lethargy or
dehydration. Survival ratios were investigated by performing the
Log-rank (Mantel-Cox) Test on Kaplan-Meier curves. All animal
experiments were reviewed and approved by The Norwegian
Animal Research Authority under study permit number 2004 190,
and conducted according to The European Convention for the
Protection of Vertebrates Used for Scientific Purposes.
Harvesting of BNML cells and phosphoproteins
Spleens were excised, segmented and diluted with 0.9% NaCl.
The filtered solution (40 mm Nylon Cell Strainer (BD Biosciences,
Franklin Lakes, NJ, USA)) was homogenized prior to isolation of
leukocytes by density gradient separation by Lymphoprep as
described by the manufacturer (Nycomed Pharma Diagnostics,
Asker, Norway).
Phosphorylated proteins from 20 million BNML blasts were
harvested using the PhosphoProtein Purification Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s description.
Phosphorylated proteins were recovered after immobilized metal-
affinity chromatography (IMAC). Following concentration by
trichloroacetic acid precipitation the washed pellets were resus-
pended in difference gel electrophoresis (DIGE) sample buffer (GE
Healthcare, Little Chalfont, UK) and frozen at 280uC
2D DIGE
Phosphoprotein samples were covalently labeled with fluores-
cent CyDyes (GE Healthcare) in a minimal labeling reaction as
described previously [27] with minor modifications; pooled,
labeled phosphoprotein samples were cup-loaded on pH 3–11
DryStrip Immobiline gel strips (GE Healthcare) prior to isoelectric
Figure 1. Gene expression analysis, phosphoproteomics and C.
elegans chemical-genetic screen identify conserved responses
to valproic acid. A) Human primary AML blasts were treated with
600 mM valproic acid (VPA), resulting in the discrimination of responsive
and non-responsive cells to VPA by gene array expression studies [14].
B) Leukemic BNML rats were treated with vehicle or VPA (170 mg/kg
b.i.d.). Phosphorylated proteins were collected from leukemic blasts
from the spleen post mortem and separated by DIGE. Differentially
represented phosphoproteins in animals treated with VPA were
identified by Orbitrap mass spectrometry. C) The Ahringer chromatin-
associated gene library was combined with 15 mM VPA for 48 hours
and screened for synthetic lethality defined by developmental arrest.
A+B+C) Functional validation of targets from all three screens (A, B and
C) by combining RNAi with VPA (15 mM) in C. elegans. The effect on
acetylation for chosen targets was investigated by immunofluorescense
in C. elegans embryos (lower panel).
doi:10.1371/journal.pone.0048992.g001
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focusing at 150 V Step 3 hours, 300 V Step 3 hours, 1000 V
Gradient 6 hours, 8000 V Gradient 2 hours, 8000 V Step
3 hours. Focused strips were further equilibrated (6 M urea, 2%
SDS, 50 mM Tris-HCl, pH 6.8, 30% glycerol) supplemented with
15 mg/ml dithiothreitol for 15 min at room temperature, followed
by 45 mg/ml iodoacetamide for 10 min. Second dimension gel
electrophoresis was performed on 26620 cm 10% Ettan DALTsix
gels casted in lab and run as described by manufacturers. Gels
were run at 6 W overnight, increasing the power to 100 W at the
end of the run. Preparative gels were dyed with SYPRO Ruby gel
staining (Bio-Rad, Hercules, California, USA) over night and
scanned by the Typhoon TRIO Variable Mode Imager (GE
Healthcare). Gels were stored in 10% ethanol at 4uC until
automatic spot picking by Ettan Spot Picker (GE Healthcare).
Software analysis of phosphoproteins
Gel images were analyzed using DeCyder 6.5 software (GE
Healthcare). Briefly, phosphoprotein spots were co-detected and
quantified in the Differential In-gel Analysis module. Protein
statistics (unpaired t-test, p,0.05) was performed in the Biological
Variation Analysis module, excluding proteins present in less than
80% of the spotmaps. SyproRuby stained single gels spots were in-
gel digested for 16 hours prior to peptide identification using the
LTQ-Orbitrap XL (Thermo Scientific, Waltham, MA, USA) as
described [28]. A minor adjustment was made increasing the
starting solvent from 0 to 7% B.
Pharmacokinetic study of VPA
280–320 g BN rats were injected with 400 mg/kg VPA (Orfiril,
injection fluid, Desitin Pharma AS) intra peritoneal at hour 0, or
administered 170 mg/kg VPA (Orfiril, oral mixture, Desitin
Pharma AS) orally at hours 0 and 8. Blood samples were collected
from the tail vein at hours 0, 1, 2, 4, 8 and 24 for the QD regimen,
and additionally at hours 9, 10 and 12 for the b.i.d. regimen.
Serum was collected by incubation for 30 minutes prior to
centrifugation at 10 000 rpm for 10 minutes. Serum concentra-
tion of VPA was measured by the Laboratory for Clinical
Biochemistry at Haukeland University Hospital according to the
producer’s recommendations, using the CEDIA Valproic Acid II
Assay (Microgenics, Thermo-Fisher Scientific, Waltham, MA,
USA) on the Modular Analytics System (Roche Applied Science,
Inc., Penzberg, Germany). Steady state levels of the drug were
calculated based on 4 and 5 half-lives of VPA.
C. elegans strains and culture conditions
C. elegans strains wild type Bristol N2, RNAi sensitive NL2099
rrf-3(pk1426), MT14480 set-11(n4488) II, NU1 bra-1(nk1) X,
VC1213 gei-8(ok1671) III, MH2430 cbp-1(ku258) III and AZ212
unc-119(ed3) ruls32[unc-119(+) pie-1::GFP::H2B] III (Caenorhabditis
elegans Genetic Center, University of Minnesota, USA) expressing
GFP in fusion with H2B, as well as the mutant strains utx-1(3136)
rescued with puts-1 UTX-1::GFP and C29F7.6 (jmjd-3.3) (kind gift
from Dr. Lisa Salcini, BRIC, University of Copenhagen) were
cultured using standard procedures at 20uC. RNA interference
(RNAi) mediated depletion of genes present in the 257 gene large
chromatin RNAi library (Source Bioscience Geneservice, Notting-
ham, UK) was performed by feeding in liquid culture with E. coli
HT115(DE3) expressing double stranded RNA (dsRNA) from the
plasmid vector L4440. The bacteria were grown overnight at 37uC
in 600 ml LB medium including 50 mg/ml Carbencillin, induced
with 4 mM IPTG at 37uC for one hour, pelleted and resuspended
in 100 ml M9 buffer.
Synthetic lethality in C. elegans
C. elegans orthologs were identified through Wormbase or by
Blast searches. Two parallel screens were performed in the
reference C. elegans wild type N2 strain and in the RNAi sensitive
rrf-3 mutant. A pilot study was performed to identify the VPA
concentration that allowed the identification of synthetic lethal
RNAi clones, as those giving severely arrested development in the
presence of VPA, and VPA-sensitizers as those that relieved or
suppressed the developmental arrest caused by VPA alone.
Approximately 20 L1 larval stage worms were dispensed per well
in 96-well flat-bottomed tissue culture plates containing 50 ml
freshly induced bacteria. Plates were incubated with shaking at
20uC for 24 hours prior to addition of 15 mM VPA. Phenotypes
were scored from 0–4 for developmental arrest 72 hours after
RNAi exposure. 0 was defined as basal level arrest observed in
untreated control worms, 1; worms arrested at L4, 2; arrested at
L2-3, 3; arrested at L1 and 4; very few surviving L1 larvae.
Positive hits were defined as those giving the same phenotype in 2
out of 3 experiments, in one or both strains. RNAi resulting in
high levels of developmental arrest not reversed or increased by
VPA were excluded from the study. The RNAi screen was
validated using available mutants; approximately 50 L1 larva of
the strains N2, set-11, bra-1, gei-8, cbp-1, utx-1and jmjd-3.3 mutant
dispensed in M9 buffer including E.coli OP50 for 24 hours at 20uC
prior to treatment with 0 mM, 1 mM or 5 mM VPA. After
72 hours of exposure to VPA the phenotypes were scored for
survival of adults. Survival was scored and presented as the
percentage of L1 that developed into adults after 72 hours from
two independent replicates with at least 50 to 100 animals per data
point.
C. elegans immunofluorescense
N2 or AZ212 L4 worms were subjected to RNAi and the
mutant strain utx-1(3136) was fed with E. coli OP50 for one hour
prior to co-exposure to 15 mM VPA for 24 hours. Gravid adults
were dissected and embryos were transferred to polylysine-coated
slide and frozen on dry ice for 20 minutes prior to fixation at
220uC for 10 minutes with methanol followed by acetone.
Embryos were immunostained using the primary antibody
Acetyl-Histone H4 (Lys8) 1:1500, primary antibody Di-Methyl-
Histone H3 (Lys36) 1:1500 (both Cell Signaling Technology, Inc.,
Beverly, MA, USA), and secondary antibody donkey anti-rabbit
alexa-555 1:1500 (Invitrogen, Carlsbad, USA) as described [29].
DAPI (200 ng/ml) (Invitrogen) was included for DNA staining
prior to visualization using a LSM-510 METAMK14, 636/1.4 oil
objective Plan-Apochromat (Carl Zeiss MicroImaging GmbH,
Goettingen, Germany), using the AxioVision Version 4.8.2
software. The degree of acetylation and methylation was scored
as the percentage of 100-cell stage embryos with positive staining
in two independent replicates with at least ten embryos per data
point.
Human AML cell culture and cell death assay
Cell lines were grown in RPMI 1640 (Gibco, Invitrogen,
Paisley, UK) (MV4-11 in IMDM (Gibco, Invitrogen)) supple-
mented with 10% fetal bovine serum gold (PAA Laboratories
GmbH, Pasching, Austria), streptomycin (5 mg/ml), penicillin
(5 U/ml), and L-glutamine (2 mM) (all from Sigma-Aldrich, St.
Louis, Missouri, USA) at 37uC with 5% CO2 in a humidified
incubator. Wild type UTX cell lines MV4-11 and NB4, and UTX
mutant cell lines MONO-MAC-1 and THP-1 (all from Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH
(DSMZ), Braunschweig, Germany) were incubated for 48 hours
in a 96-well microplate (26104 cells/well) after treatment with
VPA HDACi Function Depends on UTX
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2 mM VPA (Desitin Pharma AS). Cells were stained with 10 mg/
ml Hoechst 33342 DNA stain (Calbiochem, Merck KGaA,
Darmstadt, Germany) for one hour at room temperature prior
to examining nuclear morphology by epifluorescence microscopy
(Leica DM IRB, Leica Microsystems, Mannheim, Germany). Cells
were imaged immersed in 1:1 solution of Fluoro-gel II containing
DAPI (Electron Microscopy Sciences, Hatfield, PA, USA) using
the Axio Imager.Z1, 1006/1.4 oil objective Plan-Apochromat and
the AxioVision Version 4.8.2 software (all by Carl Zeiss
MicroImaging GmbH, Goettingen, Germany). Statistical signifi-
cance was determined using an unpaired, two-tailed t-test
(GraphPad, GraphPad Software, Inc., La Jolla, CA, USA).
MOLM-13 (DSMZ), harboring functional p53 resembling the
majority of the primary patient material [30], were added 1 or
2 mM VPA or 0.2 mM SAHA (kindly provided by Sigrid
Rasmussen, Merck Sharp, Whitehouse Station, NJ, USA)
dissolved in Dimethyl Sulfoxide (DMSO) (Lab-Scan Analytical
Sciences, Gliwice, Poland), 5 nM Geldanamycin (Sigma-Aldrich)
dissolved in DMSO, 5 mM Cytochalasin B (Sigma-Aldrich)
dissolved in DMSO or 1 nM Vincristine (Pfizer, New York, NY,
USA), or a combination of VPA and Geldanamycin, Cytochalasin
B or Vincristine, or SAHA and Geldamamycin. Cells were
incubated for 48 hours and scored for abnormal nuclei. Statistical
significance of drug interaction was determined using two-way
ANOVA (GraphPad, GraphPad Software, Inc.). MV4-11 and
NB4 cells were treated with 1 mM VPA in combination with
5 nM 17-dimethylaminoethylamino-17-demethoxygeldanamycin
(17-DMAG) (Infinity Pharmaceuticals, Cambridge, MA, USA)
dissolved in DMSO, 0.5 mM vincristine or 2 mM Cytochalasin B
for 48 hours. Viability was determined using the Annexin-V Alexa
Fluor 488 (Life Technologies Ltd, Paisley, UK) and Propidium
Iodide (PI) (Sigma-Aldrich) assay. Cells were washed in PBS and
re-suspended in binding buffer (2.5% Annexin-V Alexa Fluor
488). Samples were incubated for 15 minutes at room temperature
and added binding buffer with PI (final concentration 0.2 mg/ml).
The data were acquired on a BD Accuri C6 flow cytometer (BD
Bioscience, San Jose, CA, USA) and analyzed using the software
Flow Jo (Tree Star, Inc., Ashland, OR, USA). The percentage of
dead cells is displayed relative to untreated control cells. Statistical
significance was determined using two-way ANOVA (GraphPad,
GraphPad Software, Inc.) for synergism testing (p,0.05).
Western blotting
5–106106 cells were washed in ice cold 0,9% NaCl and
subjected to gel electrophoresis (10%) and western blotting as
previously described [31]. Anti-H3K27me3 (Active Motif, Rix-
ensart, Belgium) and anti-H2BK120ac ((07-564) Upstate Cell
Signalling Solutions) were incubated for 1 hour at room temper-
ature, anti-EZH2 ((D2C9) Cell Signaling Technologies, Billerica,
MA, USA), and anti-GST-UTX (kindly provided by Prof. Kristian
Helin [32]) was incubated overnight at 4uC. Anti-beta-actin ((sc-
2778) Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used
as loading control. IgG secondary antibodies were from Jackson
ImmunoResearch (West Grove, PA, USA). Bands were quantified
using the Kodak analysis software (Eastman Kodak Co, Rochester,
NY, USA). Data were exported to an Excel spreadsheet, corrected
for background and loading control intensities. The mean intensity
of a representative Western blot was calculated and normalized to
beta-Actin. The numbers shown are arbitrary units compared to
the intensity of the MV4-11 control or non-specific siRNA control.
siRNA knockdown
MV4-11 cells with intact p53 signalling, and p53 mutated NB4
cells were cultured as described above. Medium was replaced with
penicillin-free medium the day before the experiment. siRNA
knockdown was performed three times in triplicate using the Neon
Transfection System according to the suppliers recommendations
(Invitrogen). Briefly, 0.26106 cells, or 16106 cells for western blot,
were electroporated with ON-TARGETplus SMARTpool UTX
siRNA (Thermo Scientific, Inc. for MV4-11 cells), UTX siRNA
(Qiagen, Inc. for NB4 cells), or negative control (AllStars Negative
Control Alexa Fluor 488 siRNA, Qiagen) prior to plating in a 96
or 6 well plate, respectively, at a total concentration of 600 nM.
2 mM VPA was added after 18 hours and cells were incubated for
additionally 48 hours, prior to scoring for abnormal nuclei as
described above. For Western blotting, cells were incubated for
24 hours with negative control or UTX siRNA at a total
concentration of 600 nM prior to cell lysis and gel electrophoresis
as described above. Statistical significance of drug and siRNA
interaction was determined using an unpaired, two-tailed t-test
(GraphPad, GraphPad Software, Inc.).
Small-scale data integration
Data from all screens were combined in silico for extraction and
prediction of common functionalities and components; Lists of
direct protein-protein interactors as well as indirect interactors
mediated via one neighbors were extracted using FunCoup
(Stockholm Bioinformatics Centre, http://funcoup.sbc.su.se)
[33]. Next, the results from each individual screen were combined
to find common hits across the different screens. The lists were
imported into Cytoscape (http://www.cytoscape.org) [34] in order
to find enriched Biological Processes using the plug-in program
BiNGO (Flanders Interuniversitary Institute for Biotechnology,
http://www.psb.ugent.be/cbd/papers/BiNGO/Home.html) [35].
False discovery rate was controlled by the Benjamini-Hochberg
procedure, correcting the p-values for functional coupling of the
proteins.
Results
Genes induced by VPA in non-responsive AML patient
cells reflect resistance mechanisms
We previously identified genes up-regulated in response to VPA
(Table S1; ABCA5, AGPAT4, BAG2, COCH, FLIPT1, WDR35,
EID3, KCNA3, MAD1, SERPINF1, SMAD3, AKT3, IL12RB2,
NDRG2) in AML cells isolated from responding and non-
responding patients in vitro [14], and hypothesized that AML cells
proliferating in the presence of VPA (non-responsive) induced
genes that contributed to resistance. To test this hypothesis we
assessed whether depletion of these genes exacerbated or
suppressed the developmental arrest phenotype induced by VPA
in C. elegans (Figure 1).
Synthetic lethal interactions were defined as a combination of
VPA and RNAi that led to arrest at earlier developmental stages
than by either treatment alone. Conversely, if genes up-regulated
in the responding primary cells reflect a mechanistic function we
would expect to see RNAi-induced suppression of the VPA-
induced phenotype – such genes were therefore defined as
sensitizers of VPA: No such sensitizers of VPA were found.
Contrary to this, we found that depletion of orthologs of the six
genes that were up-regulated in the VPA-non-responsive cells
resulted in synthetic lethality, thereby confirming our hypothesis
(Table S1). However, 5 out of 15 genes up-regulated in the
responsive cells also resulted in synthetic lethality (Table S1). Thus,
genes transcriptionally up-regulated in both non-responding and
responding leukemic patient cells may contribute to cell survival in
the presence of VPA.
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Establishment of a BNML leukemic rat VPA progressive
disease model
To further explore the VPA-resistance mechanisms we utilized
the Brown Norwegian myeloid leukemia (BNML) syngeneic rat
leukemia model which provides highly reproducible responses to
conventional chemotherapeutics [18,36] with the advantage of a
complete host immune system during leukemia growth and
therapy. We developed a progressive disease model in the BNML
rats by giving animals suboptimal doses of VPA (170 mg/kg b.i.d.).
This dose level partly reflects the clinical situation when VPA-dose
is reduced due to adverse effects like drowsiness [13]. The rats
presented with a progressive, minimally-responsive disease.
Treatment with 400 mg/kg VPA, however, resulted in survival
for the duration of VPA therapy in this experiment (4 weeks)
(Figure 2A), reflecting the potential of high dose VPA to prevent
disease progression. However, lower level dosing resulted in a
minimal, yet significant, extension of the median survival from 30
to 32.5 days (p = 0.0037) (Figure 2B) similar to the progressive
disease often observed in advanced AML patients treated with
VPA [13,37]. Both doses give clinically relevant steady state serum
concentrations of 174–361 mM and 250–500 mM for the high and
low dose model, respectively (Figure S1). The high dose treatment
results in consequently higher VPA serum concentrations during
the first eight hours, compared to the low dose. Additionally, the
high dose gives higher average area under the curve (AUC) values
1 354 and 880 mM/hour by the linear and logarithmic trapezoidal
method, respectively, compared to 372 and 356 mM/hour by the
low dose. We therefore believe the peak concentration and the
AUC of the drug, and not the steady state levels to be determinant
of VPA responsiveness. Death by progressive leukemia was
confirmed by necropsy, revealing extensive splenomegaly and
hepatomegaly compared to untreated BN rats. Hence, the low
dose VPA regime represents an in vivo model of progressive
leukemic disease on treatment with VPA.
VPA regulates phosphoprotein expression in progressive
leukemic disease
We used phosphoproteomics to identify active signaling
pathways induced by VPA in the BNML rat VPA-minimal-
response model. Phosphorylated proteins from spleen-derived
leukemic cells were collected at the defined disease endpoint,
mimicking progressive disease and VPA therapy failure
(Figure 1B). Twenty-one differentially expressed phosphoproteins
(p,0.05) were identified by linear quadrupole ion trap-Orbitrap
(LTQ-Orbitrap) Mass Spectrometry (Table 1).
Among the differentially phosphorylated proteins were eleven
that participate, or are predicted to act, in the resistance pathways
identified from the gene expression analysis [14] (Figure S2);
Phosphoproteins involved in ubiquitin dependent protein degra-
dation, (PSME2 and HSC70), oxidative stress/MAPK signaling
(MAPK1, eEF1D), TGFb signaling (SHIP1), mitochondrial ATP
synthesis/oxidative phosphorylation (OPA1, UQCRC2), and
intracellular transport (TUBA1B (tubulin), DYN2 (Dynamin 2),
ACTB (actin), MOESIN) were differentially represented in the
VPA-treated rats. The enrichment of cytoskeletal proteins was
consistent with a requirement for the cytokinesis checkpoint for
sustained proliferation in the presence of VPA. Functional
validation in C. elegans showed that synthetic lethality was observed
for 7 out of the 11 genes investigated (Table 1). In contrast to the
severe toxicity associated with depletion of classical checkpoint
proteins, the targets identified here resulted in low or no toxicity in
absence of VPA, emphasizing their potential for development as
combination therapy.
Abrogation of conserved resistance pathways sensitizes
human AML cells to VPA
Although VPA is a HDACi [38] we found a striking under-
representation of genes involved in chromatin remodeling in the
above analyses, with SET and NUCB2 being the only DNA
binding proteins identified in the phosphoproteomic screen
(Table 1). To identify functional interactions between VPA and
genes participating in chromatin associated processes, we screened
a focused C. elegans RNAi library that identified 43 genes that
modulated VPA-induced developmental arrest of which an
additional 28 synthetic lethal clones were identified, 6 of which
are predicted, or known, transcriptional regulators (Table 2,
Figure 1C).
Although there was no direct overlap between datasets
harvested through the different methods used, the individual
datasets indicated modulation of similar pathways or biological
processes. To extract the common processes reflected in all
Figure 2. Survival of leukemic BN rats without and with
valproic acid treatment. A) BN rats were injected with 106106 BNML
cells on day 0 before treatment started on day 10. Animals were treated
with vehicle or VPA intra peritoneal (400 mg/kg) for 5 days, with 2 days
off, in total for four weeks. Animals did not display symptoms for
leukemia until termination of treatment, representing a responsive VPA-
model. B) BN rats were injected with 56106 BNML cells on day 0 before
treatment (170 mg/kg VPA, per orally) started at day 16. Animals were
treated successively with 170 mg/kg VPA b.i.d. from day 17. Animals
treated with VPA showed significantly increased survival compared with
control rats (median survival increased from 30 to 32.5 days, p = 0.0037).
However, the disease progressed and animals displayed high leukemic
burden upon sacrifice at humane endpoint, representing a VPA-
resistant model. Red marks represent days of treatment, grey marks
represent no treatment.
doi:10.1371/journal.pone.0048992.g002
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approaches we analyzed the overlap based on gene ontology (GO)
annotation. The biological processes emerging from the three lists
show remarkable similarities (Figure 3A). In particular, TGFb and
oxidative stress/MAPK signaling, ubiquitin dependent protein
degradation, as well as maintenance of chromatin structure and
the cytokinesis checkpoint are conserved processes modulated by
VPA. Several of these pathways have been found to be regulated
by VPA. The combination of VPA and the proteasome inhibitor
bortezomib synergistically increased apoptosis and decreased
proliferation in the AML cell line HL60 [39]. Further, genes
active in the MAPK, ubiquitin-mediated proteolysis and TGFb
signaling pathways have been found to be up-regulated in response
Table 1. Valproic acid-modulated phosphoproteins from BNML rat leukemia progressive disease.
DeCyder Protein Analysis Synthetic lethality Gene information
Protein Ratio (VPA/CTR) p-value C. elegans gene Synthetic lethal Gene Biological process
1 SPG21 21,97 0,0059 * Spg21 Cell death, CD4 activation
2 PAI-RBP1 vig-1 Y Serbp1 Regulation of mRNA stability, regulation of
anti-apoptosis
ATPA1 21,96 0,05 H28O16.1 Y Atp5a1 Negative regulation of endothelial cell
proliferation, ADP
and ATP biosynthesis
3 HK1 21,7 0,024 H25P06.1 Y Hk1 Glycolysis
SHIP1 * Inpp5d Negative regulation of cell proliferation
4 OPA1 21,55 0,025 eat-3 Y Opa1 Apoptosis, mitochondrial organisation
DYN2 * Dnm2 Endocytosis, G2/M transition of cell cycle
5 MOESIN 21,38 0,0043 * Msn Leukocyte migration and cell-cell adhesion
6 GOT2 21,33 0,022 * Got2 Cellular amino acid metabolic process, fatty
acid
transportation
7 HPRT1 21,29 0,032 Hprt1 Lymphocyte proliferation, nucleoside
metabolism
8 PRPSAP2 0,016 W04G3.5 Y Prpsap2 Nucleoside metabolism, regulation of
transcription
MAPK 1,38 * Mapk1 Induction of apoptosis, regulation of
proliferation, DNA damage response
9 HSC70 1,39 0,0083 hsp-1 - Hspa8 Unfolded protein response
10 TUBA1B 1,41 0,017 tba-2 - Tuba1b Microtubule cytoskeleton organization
PPM1F * Ppm1f Apoptosis, protein dephosphorylation
11 UQCRC2 1,42 0,046 ucr-2.2 - Uqcrc2 Oxidative phosphorylation, proteolysis
12 NAGK 1,45 0,043 * Nagk N-acetylglucosamine metabolic process
13 NUCB2 1,48 0,034 * Nucb2 DNA binding
14 eEF1D 1,53 0,039 * Eef1d Translational elongation, positive regulation
of I-kappaB
kinase/NF-kappaB cascade
15 GMFG 1,57 0,037 * Gmfg Growth factor activity, protein
phosphorylation
16 LXN 1,65 0,000077 * Lxn Enzyme and metalloendopeptidase inhibitor
17 APRT 1,67 0,014 T19B4.3 Y Aprt Purine salvage, nucleoside metabolism
18 ACTB 1,67 0,043 act-5 ** Actb Cellular component movement,
axonogenesis
NUDC nud-1 Y Nudc Cell proliferation and cytokinesis
19 SET 1,75 0,00075 * Set Negative regulation of histone acetylation,
DNA replication
20 PSME2 1,8 0,00047 * Psme2 Proteasome activator
21 ACTB 1,96 0,019 act-5 ** Actb Cellular component movement,
axonogenesis
Control -
Positive values of ratios between VPA-treated and control animals indicate proteins with elevated expressed level, negative values are proteins with reduced expression
in VPA treated animals.
*RNAi was not performed.
**Synthetic lethality could not be assessed because of severe developmental arrest by RNAi alone.
doi:10.1371/journal.pone.0048992.t001
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Table 2. VPA-synthetic lethal or -sensitizer genes identified from the chromatin library screen in C. elegans.
Sequence name C. elegans gene Human gene Biological process of C. elegans gene
VPA-synthetic lethal genes
T27F2.1 skp-1 SNW1 Chromatin binding and nuclear mRNA splicing
D1081.8 phi-7 CDC5L DNA damage response, mRNA splicing factor
F45E1.6 his-71 H3F3B DNA damage response, nucleosome assembly
W05B10.1 his-74 H3F3B DNA damage response, nucleosome assembly
Y49E10.6 his-72 H3F3B DNA damage response, nucleosome assembly
C12C8.3 lin-41 TRIM71 Predicted E3 ubiquitin ligase, negative regulation of
translation
T11A5.1 lys-12 MYST3 Histone acetyl transferase
T08D10.2 lsd-1 KDM1A Lysine-specific histone demethylase
F34D6.4 set-11 EHMT2 Putative histone H3 lysine-9 methyltransferase
R06F6.4 set-14 SMYD3 Predicted histone tail methylase
ZC8.3 set-30 SMYD3 Predicted histone tail methylase
C14B9.6 gei-8 NCOR1 Likely homolog of co-repressor NCoR/SMRT
F08G2.2 his-43 HIST2H2AB Nucleosome assembly
F08G2.3 his-42 HIST2H3D Nucleosome assembly
F17E9.13 his-33 HIST2H2AB Nucleosome assembly
F17E9.9 his-34 HIST2H2BF Nucleosome assembly
F54E12.5 his-57 HIST2H2AB Nucleosome assembly
F55G1.10 his-61 HIST2H2AB Nucleosome assembly
F55G1.3 his-62 HIST2H2BB Nucleosome assembly
H02I12.7 his-65 HIST2H2AB Nucleosome assembly
T10C6.12 his-3 HIST2H2AB Nucleosome assembly
T23D8.6 his-68 HIST2H2AB Nucleosome assembly
ZK131.10 his-16 HIST2H2AB Nucleosome assembly, defence response
F54B11.6 bra-1 ZMYND11 Negative regulation of TGF-beta receptor signalling pathway
B0019.2 B0019.2 * Regulation of transcription
F43G9.12 F43G9.12 C21orf66 Regulation of transcription
R10E11.1 cbp-1 CREBBP Regulation of DNA dependent transcription, positive
regulation of RNA polymerase II promoter
F54F2.9 F54F2.9 DNAJC1 Predicted unfolded protein binding
VPA-sensitizer genes
C44F1.2 attf-1 GMEB1 AT hook transcription factor family
F13C5.2 F13C5.2 BRD2 Bromodomain containing protein
F37A4.8 isw-1 SMARCA1 ATP-dependent chromatin remodelling
F11A10.1 lex-1 ATAD2B Chromatin structure and transcription
F02D10.7 set-8 WHSC1L1 DNA damage response
ZC155.2 ZC155.2 * Protein harbouring core histone domains
D2021.1 utx-1 KDM6A Histone H3 di/trimethyllysine-27 (H3K27me2/me3)
demethylase
C29F7.6 C29F7.6 JMJD3 Putative histone H3 di/trimethyllysine-27 demethylase
F18E9.5 tag-279 UTY Histone H3 trimethyllysine-27 (H3K27me3) demethylase
K09F5.5 set-12 SETD2 Histone-lysine N-methyltransferase activity
R11E3.4 set-15 EHMT2 Predicted histone H3 (Lys9) methyltransferase
F25C8.2 amx-3 SMOX Metabolic process
F22F1.1 hil-3 HIST1H1B Nucleosome assembly
Y113G7B.14 Y113G7B.14 TTF2 RNA polymerase II transcription termination factor family
C49F5.5 C49F5.5 EP300 Regulation of DNA-dependent transcription
*No corresponding human homolog.
doi:10.1371/journal.pone.0048992.t002
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to treatment with VPA and hydralazine in breast cancer patients
[40]. Next, we supplemented the primary data with predicted
protein-interaction partners extracted using FunCoup [33] to see
whether a direct overlap between all methods and model systems
could be revealed. As anticipated an overlap emerged for proteins
extracted from all models (Figure 3B, yellow diamonds). The
resulting predicted network includes several primary hits
(Figure 3B, in red) converging on MAPKAPK2, ACTB,
HSP90AA2 and HSP90AB1, suggesting that these are key proteins
responding to VPA. Loss of BAG2 (unc-23, a direct interactor of
MAPKAPK2) sensitized C. elegans to VPA (Table S1). We
confirmed that other components of this conserved network
promote survival in response to VPA also in human cells.
Significantly increased VPA sensitivity was seen after concomitant
inhibition of tubulin polymerization by vincristine (VCR)
(Figure 3C and D), actin polymerization by cytochalasin B
(Figure 3E), or HSP90 by geldanamycin (GA) (Figure 3C and F) in
the MOLM-13 and the MV4-11 AML cell lines (Figure S3). In the
p53 negative AML cell line NB4, synergy was observed by VPA
and cytochalasin B treatment (Figure S3). Importantly, potentia-
tion of cytotoxicity beyond the theoretical additive effect by GA
was found also when combined SAHA in MOLM-13 (Figure 3G).
Hence, the conserved resistance program identified for VPA is
valid also for other clinically useful HDACi.
A synthetic lethal screen in C. elegans identify histone
demethylases as sensitizers of VPA-induced
developmental arrest
Unlike gene expression arrays and phosphoproteomic screens,
the C. elegans RNAi screen also revealed a high number of genes
(15 out of 48) which suppressed the developmental arrested
phenotype of VPA when depleted by RNAi (Table 2). These genes
were termed VPA-sensitizers as they likely mediate VPA arrest.
That five out of 15 sensitizers are known, or predicted to have
histone methyltransferase or demethylase activity, suggests that the
hyperacetylated state induced by VPA requires additional changes
in chromatin state to induce cytostatic effects. All sensitizers, apart
from set-8 and amx-3, have DNA binding activity. We conclude
that extensive epigenetic chromatin modification is required for
cytostatic effects of VPA.
Given the complex regulation of histone marks, it was not
unexpected that genes encoding histone methylation (set-11
(EHMT2), set-12 (SETD2), set-15 (EHMT2) and set-30 (SMYD3))
as well as histone demethylation (C29F7.6 (JMJD3), utx-1
(KDM6A) and tag-279 (UTY)) activities were recovered as both
sensitizers and synthetic lethal interactors. Furthermore, we used
available C. elegans mutant strains of VPA synthetic lethal- as well
as sensitizer-genes to validate the RNAi screen and found that
mutants of sensitizer genes showed decreased sensitivity to VPA,
and conversely, mutants in genes identified as synthetic lethal
interactors showed increased VPA sensitivity (Figure S4). In light
of the results from the gene expression array and the phospho-
proteomic screen, it is intriguing that depletion of a negative
regulator of TGFb signaling, bra-1 (ZMYND11) increases the effect
of VPA treatment. BRA-1 was suggested to link TGFb signaling
with chromatin remodeling [41]. Hence, the ability of VPA to
modulate chromosome dynamics and epigenetic histone marks
appear central to the cytostatic effect of VPA.
Hyperacetylation of H4K8 correlates with the
developmental arrested phenotype in C. elegans
As a direct read-out of VPA action we monitored the acetylation
status of Histone 4 Lysine 8 (H4K8ac), considered to be enriched
in transcriptionally active chromatin and independent of DNA
damage [42]. In VPA-treated animals, H4K8ac was readily
detected at the 100-cell stage (Figure 4) whereas strong H4K8ac
staining was first seen approximately at the 200-cell stage in
untreated controls (Figure S5A). Hence, as expected from an
HDACi, VPA induces a state of histone hyperacetylation in the
early embryo and H4K8ac can be used to test whether VPA-
regulated genes and proteins directly affect histone acetylation in
vivo.
Whereas no change was seen in global H4K8ac levels after
depleting two synthetic lethal interactors (oct-2 (FLIPT1) and vig-1
(SERBP1), data not shown), depletion of all three VPA-sensitizers
tested (set-12 (SETD2), utx-1 (UTX), and lex-1 (ATAD2B)) gave
increased baseline staining for H4K8ac (Figure 4). This suggests
that these gene products may interfere with the proper function of
HDA-1 (HDAC1) deacetylation activity in early embryos and that
elevated histone acetylation levels increases the sensitivity to
HDACi.
UTX mutated cells display reduced VPA sensitivity
To validate that the sensitizers identified in C. elegans had a
similar function in human AML cells, we focused on UTX as UTX
(utx-1) mutations have been found in the AML cell lines MONO-
MAC-6, THP-1 [43], and in patients with myelodysplastic
syndrome [44]. If UTX was a sensitizer of VPA responses, we
would predict that it contributes to regulate genes that are
activated by VPA. Subsequently, we found several promoters of
genes identified as differentially regulated by VPA in human AML
patients [14] were consistently occupied by UTX in chromatin
immunoprecipitation experiments [45], and human orthologs of
synthetic lethal interactors identified here were bound by UTX
(Table S2).
The association between histone acetylation and methylation
observed in C. elegans was also evident in a panel of AML cell lines,
including THP-1 cells harboring a deletion comprising exons 1–16
in the UTX (utx-1) gene and no detectable protein expression [43].
The expected increase in histone acetylation after VPA treatment
was observed in MV4-11 and NB4 cells concomitant with
increased H3K27me3 (Figure 5A). Neither histone mark was
induced by VPA in the UTX-null line THP-1, consistent with the
hypothesis of UTX being contributing to VPA function. A
comparison of VPA sensitivity in human AML cell lines
demonstrated that two cell lines harboring mutated UTX (utx-1),
namely THP-1 and MONO-MAC-1, were significantly less
sensitive to VPA-induced cell death (Figure 5B and C), revealing
UTX as a sensitizer of VPA toxicity also in human AML cells. A
mechanistic requirement for UTX for VPA-response was further
confirmed by knock down of UTX by siRNA in the highly VPA-
sensitive MV4-11 cell line (Figure 5D) (60% knockdown efficien-
cy), resulting in significantly reduced VPA-induced cell death
(p = 0.014) in cells depleted for UTX prior to exposure to 2 mM
VPA compared to cells receiving non-targeting siRNA control.
UTX siRNA knock down in the p53 mutated cell line NB4 (60%
knock down efficiency) resulted in slightly reduced sensitivity
towards VPA (Figure 5D) suggesting that UTX is a conserved
sensitizer of VPA induced hyperacetylation and cytotoxicity.
Furthermore, C. elegans embryos treated with utx-1 (UTX) RNAi or
being heterozygous of utx-1 showed reverse H4K8ac and
H3K36me2 responses to VPA compared to wild type AZ212
worms. This result could indicate that UTX affects the epigenetic
regulation by VPA not only directly through H3K27 trimethyla-
tion, but also through general histone demethylation and its
activities as an HDACi.
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Discussion
In order to identify genes and proteins that mediate resistance to
the HDACi VPA in AML patients, we used a novel combination
of models and technology that allowed us to address the
mechanism of VPA induced toxicity at multiple levels. First, as
an HDACi, VPA is expected to affect gene expression (VPA-
regulated genes in AML patients) [14]. Second, this would lead to
changes in cellular signaling pathways (probed by an in vivo rat
leukemia phosphoproteomic screen) and off-target mechanisms
that affect the specific biological endpoint, namely VPA sensitivity
or resistance (C. elegans functional validation). Bioinformatic data-
integration helped us identify a small set of conserved genes and
pathways that were functionally validated in human cell lines to be
VPA-sensitizers or to promote VPA resistance. We propose this to
be a powerful strategy to facilitate the translation of complex
datasets into clinically useful biomarkers and therapy targets for
VPA.
Whereas all experimental approaches successfully revealed
genes that confer resistance to VPA, the C. elegans chemical
genetic screen also revealed mechanistically important genes
required for VPA action where a direct modification of the
chromatin acetylation state by VPA was demonstrated. Interest-
ingly, several histone demethylases and methyltransferases were
required for VPA induced developmental arrest. In embryos
depleted for these VPA-sensitizers, the global histone acetylation
levels were elevated even in the absence of VPA (Figure 4),
suggesting that the sensitizers directly or indirectly restrict histone
acetylation. Interestingly, the histone acetylation state was elevated
to a similar degree by the two methylation-modulating proteins
UTX-1 (UTX), a histone H3 lysine 27 (H3K27) di/trimethyl
demethylase and SET-12 (SETD2), a histone methyltransferase.
This may suggest that removing either activity will result in
destabilization of the methylation pattern of histone H3, permit-
ting access to chromatin for HATs. The recent demonstration that
human UTX associates with the H3K4me3 histone methyltrans-
ferase MLL2 [45] supports a model in which the coordinated
removal of repressive marks and deposition of activating marks are
important for regulation of transcription during cellular differen-
tiation. The complex inter-regulation of different histone marks is
illustrated in C. elegans where VPA treated embryos was depleted of
H3K36me2 (Figure S5B) and in human cells by the increase in
histone H3K27me3 in response to VPA (Figure 5A, Figure S6). A
role for UTX as a sensitizer of cellular responses to VPA was also
confirmed in human cells where two human AML cell lines with
impaired UTX function showed VPA resistance (Figure 5B). The
UTX loss of function mutant cell line THP-1 did not display
similar histone modification changes in response to VPA as seen in
UTX-proficient AML cell lines (Figure 5A). Furthermore, the
depletion of UTX (utx-1) in the highly VPA-sensitive cell line
Figure 3. Conserved pathways contribute to VPA resistance. A) The human homologs/orthologs of data from all screens were combined in
an in silico approach to extract and predict common functionalities and components. Proteins identified in our datasets (red), as well as direct
interactors and indirect interactors (black) mediated via one neighbor extracted by the FunCoup browser, were imported into Cytoscape which
returned five clusters of enriched process which were manually grouped (grey shade) to illustrate that ‘‘APC-dependent proteasomal ubiquitin-
dependent protein degradation’’ and ‘‘Response to unfolded protein’’ are the major conserved processes responding to VPA. In addition, ‘‘Regulation
of TGFb receptor signaling’’ and ‘‘Transport’’ are also functionally important in providing resistance to VPA. The scale depicts color representation of
significance by Benjamini-Hochberg correction, where white nodes are not significant, yellow p,0.05 and orange p,761027. B) Protein interaction
network reveal conserved hubs that promote VPA resistance. Data from all screens were combined in silico and the functional interaction network
among the common proteins (diamonds) were extracted using FunCoup. ACTB, HSC70, and TUBA1B (red) were in the primary list whereas
MAPKAPK2, HSP90AA2 and HSP90AB1 (black) were identified in all approaches as interactors. ACTB, HSC70, HSP90AA2, HSP90AB1 and TUBA1B
represent evolutionary conserved nodes providing resistance to VPA. C) VPA (1 mM) was combined with inhibitors of tubulin (vincristine (VCR), 1 nM)
or HSP90 (geldanamycin (GA), 5 nM) in MOLM-13 AML cells and investigated for effects on apoptosis measured by Hoechst staining after 48 hours of
treatment. Arrows indicate fragmented and condensed nuclei. Scale bar = 10 mm. Combinations of 1 mM VPA and 1 nM vincristine (D), 2 mM VPA
and inhibitor of actin polymerization cytochalasin B (E), 1 mM VPA and 5 nM geldanamycin (F), and 0.2 mM SAHA and 5 nM geldanamycin (G) all
show statistically significant synergism of drug interaction, two-way ANOVA, * p,0.05, ** p,0.001, *** p,0.0001. Error bars represent standard error
of mean (SEM).
doi:10.1371/journal.pone.0048992.g003
Figure 4. Histone methylation capacity affects basal histone acetylation in C. elegans embryos. VPA-treatment induced global acetylation
in 100-cell stage C. elegans embryos. The strain AZ212, expressing GFP in fusion with H2B, was fed the empty vector L4440 (RNAi), the VPA-sensitizers
lex-1 (RNAi), utx-1 (RNAi) (histone demethylase), and set-12 (RNAi) (histone methyltransferase), and exposed to 15 mM VPA at L4 larval stage for
24 hours at 20uC. The embryos were fixed with acetone and methanol prior to staining with an Acetyl-Histone H4 (Lys8) antibody. At the 100-cell
stage, baseline levels of acetylation were seen in untreated control worms. Global hyperacetylation was observed after treatment with VPA by all.
Depletion of lex-1, utx-1 and set-12 gives increased baseline acetylation in the absence of VPA. Scale bar = 10 mm.
doi:10.1371/journal.pone.0048992.g004
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MV4-11 resulted in a significant (p = 0.014) decrease in cell death
when subjected to VPA (2 mM) (Figure 5D). This confirms a role
of UTX in mediating the VPA response. Hence, UTX (also
known as KDM6A) -mediated histone di/trimethyl demethylation
results in a more open and active chromatin conformation [46], is
here revealed as a requirement for HDACi function. As such,
functional UTX (utx-1) expression may serve as a biomarker for
optimal therapeutic effect of this drug in patients. As an interesting
parallel, over-expression of a related histone lysine demethylase,
KDM5A, was recently shown to be a possible mediator of broad-
spectrum drug-tolerance [47]. It was proposed that altered
regulation of chromatin structure or histone marks was an
underlying mechanism of reversible tolerance to a wide spectrum
of anti-cancer drugs, an observation supported by this study.
However, the synthetic lethal interactors identified here show that
the increased histone acetylation resulting from inhibition of
HDAC class I and II by VPA can, to some degree, be
compensated for by activation of tolerance programs.
Our data is further corroborated by clinical trials identifying the
TGFb pathway to be regulated by VPA in breast cancer [12] and
reports of deregulated TGFb signaling in leukemogenesis [48]. A
role of TGFb signaling in response to VPA was reflected in all our
datasets and identification of BRA-1 (ZMYND11), a negative
regulator of TGFb signaling in C. elegans, as a synthetic lethal
interactor provides support for direct regulation of TGFbin
addition to an up-regulation of TGFb negative regulators via
AKT inhibition as suggested previously [49].
Increased PAI-RBP1 (the protein of the gene SERBP1 (vig-1))
expression was found in chronic lymphocytic leukemia [50] and
correlated with tumor progression in epithelial ovarian cancer
[51]. Our results points to a possible function for PAI-RBP1 also in
AML.
Finally, bioinformatic integration of the datasets offered a way
to meet the lack of direct overlap between molecules and genes
which has been a common criticism of medium- and high-
throughput screening methods. This revealed that MAPKAPK2,
ACTB, HSP90AA1 and HSP90AB1 are evolutionary conserved
hubs that allow cells to continue proliferation in the presence of
VPA. Interruption of these hubs using small molecule inhibitors
increased the effect of VPA in the human AML cell lines (Figure 3).
Hence, these survival pathways should be further explored for
development of new low toxicity therapeutic combinations with
VPA.
Supporting Information
Figure S1 Pharmacokinetics of VPA in BN rats. Serum
levels were measured in A) the QD (once daily) high dose model
(400 mg/kg) and B) the b.i.d. low dose model (170 mg/kg b.i.d.) at
the indicated time points. Due to the administration regime of the
drugs, the QD model (A) is represented by a steadily decaying
curve, whilst the twice daily model (B) is represented by a biphasic
curve with maximum serum concentration at one hour post
treatment. Steady state VPA serum concentrations were calculated
based on 4 and 5 times half-life of the drug giving 174–361 mM
and 250–500 mM for the high and low dose respectively. Error
bars represent standard errors of mean (SEM).
(PDF)
Figure S2 Network of enriched biological processes
identified by proteomics. Phosphoproteins responding to
VPA (red) as well as direct protein-protein interactors and indirect
interactors (black) mediated via one neighbor were extracted using
FunCoup and imported into Cytoscape in order to find enriched
Biological Processes using the plug-in program BiNGO. The
enriched processes were manually grouped into five major clusters
to illustrate that ‘‘Regulation of translation and signaling’’,
‘‘Regulation of ubiquitin ligase activity’’, ‘‘APC-dependent
proteasomal ubiquitin-dependent protein degradation’’, ‘‘Purine
nucleotide salvage’’ and ‘‘Energy and oxidative phosphorylation’’
are modulated by VPA in leukemic BN rats. The scale depicts
color representation of significance by Benjamini-Hochberg
correction, where white nodes are not significant, yellow p,0.05
and orange p,761027.
(PDF)
Figure S3 VPA combined with inhibition of conserved
pathways results in synergistic cell death. The AML cell
lines MV4-11 and NB4 were treated with 1 mM VPA and A)
inhibitor of HSP90 (17-DMAG, 5 nM), B) tubulin (vincristine,
0.5 mM) or C) actin polymerization (cytochalasin B, 2 mM) for
48 hours prior to analysis for cell death by the Annexin-V/
Propidium Iodide viability assay. All combinations showed
resulted in statistically significant synergism of drug interaction.
Data are shown normalized to untreated control cells. Two-way
ANOVA; * p,0.05, ** p,0.001. Error bars represent standard
errors of mean (SEM).
(PDF)
Figure 5. UTX-1 is required for VPA action in C. elegans embryos and in human cells. A) Two UTX wild type cell lines (MV4-11 and NB4) as
well as the UTX mutant cell line THP-1 were treated with 1 mM VPA for 48 hours and analyzed for H3K27me3 and H2BK120ac expression. The mean
intensity on one representative Western blot was calculated and normalized to beta-actin. The numbers shown are in arbitrary units compared to
MV4-11 control. Blots show the increase of H3K27 trimethylation as well as an increase in the degree of H2BK120 acetylation except THP-1, where the
level of methylation is unchanged and level of acetylation is decreased. B) AML cell lines with mutated UTX are resistant to VPA. MV4-11 and NB4 as
well as two UTX mutant cell lines (MONO-MAC-1 and THP-1) were subjected to 2 mM VPA for 48 hours and scored for abnormal nuclei by Hoechst
staining. * indicates t-test versus MV4-11, x indicates versus NB4. ***/xxx p,0.0004. Error bars represent SEM. C) The mutant cell lines show decreased
apoptosis, determined by Hoechst staining compared to the wild type cells. Arrows indicate fragmented and condensed nuclei. Scale bar = 10 mm. D)
MV4-11 or NB4 cells were subjected to 600 nM UTX siRNA or negative control siRNA for 18 hours prior to 48 hours treatment with 2 mM VPA. Cells
were scored for abnormal nuclei by Hoechst staining, showing UTX siRNA to reduce the effect of VPA on cell death. Values are normalized against
untreated cells. ** indicates t-test of UTX siRNA versus negative control siRNA, p = 0.014. Error bars represent SEM. E) Western blot of MV4-11 or NB4
cells treated with 600 nM negative control siRNA or UTX siRNA for 24 hours. Numbers shown are arbitrary units compared to negative control siRNA.
The blot shows a 60% decrease in UTX by siRNA treatment, confirming the efficacy of transfection. F) The C. elegans strain AZ212 was fed the empty
vector L4440 or utx-1 (RNAi), and the utx-1(3136) mutant was fed E. coli OP50 and exposed to 15 mM VPA at L4 larval stage for 24 hours at 20uC. The
embryos were immunostained using antibodies recognizing H4K8ac. In the 100-cell stage embryos, baseline levels of this activating acetylation mark
were observed in untreated control worms, whereas the utx-1 (RNAi) and utx-1(3136) mutant worms showed highly increased acetylation levels (100%
and 76% acetylation, respectively). Error bars represent SEM. G) Worms were treated as in F) and stained with a H3K36me2 antibody. At the 100-cell
stage, control embryos showed 73% methylation while both utx-1 (RNAi) and the utx-1(3136) mutant showed baseline methylation. By VPA
treatment, control worms show baseline methylation whereas both utx-1 (RNAi) and utx-1(3136) mutant shows 86% and 67% methylation
respectively. Error bars represent SEM.
doi:10.1371/journal.pone.0048992.g005
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Figure S4 C. elegans mutant strains of VPA sensitizer
genes are less sensitive to VPA. C. elegans strains of genes
mutant for VPA synthetic lethal and VPA sensitizer genes were
obtained and treated with 0, 1 or 5 mM VPA for 72 hours. The
mutants for synthetic lethal genes all showed decreased adult
worm survival with increased concentrations of VPA. Sensitizer
mutant strains showed no or little decrease in survival by 1 mM
VPA, and increase in death only when treated with 5 mM VPA.
However, this survival was substantially higher in sensitizer
mutants (mean survival 46–60%) compared to synthetic lethal
mutants (1–20% mean survival). Error bars represent SEM.
(PDF)
Figure S5 VPA treatment induced global demethylation
in 100-cell stage C. elegans embryos. C. elegans strain AZ212,
expressing GFP in fusion with H2B, was fed the empty vector
L4440 (RNAi) and exposed to 15 mM VPA at L4 larval stage for
24 hours at 20uC. A) H4K8Ac appears at about the 100 cell stage
in VPA-treated embryos but first at the 200 cell stage in untreated
embryos. B) The embryos were fixed with acetone and methanol
prior to staining with di-Methyl-Histone H3 (Lys36) antibody. At
the 100-cell stage, baseline levels of methylation were seen in
untreated worms. Global demethylation was observed after
treatment with VPA suggesting a functional relationship between
protein acetylation and lysine-specific methylation. Scale
bar = 10 mM.
(PDF)
Figure S6 VPA regulation of epigenetic marks. AML cell
lines were treated with 1 mM VPA for 48 hours and analyzed for
EZH2, H3K27me3 and H2BK120ac expression. The mean
intensity on one representative Western blot was calculated and
normalized to beta-Actin. The numbers shown are in arbitrary
units compared to MV4-11 control. A) The effect on VPA on
EZH2 expression is not dependent on the expression of UTX. B)
VPA increases the degree of H3K27 trimethylation in all cell lines
except the UTX-null THP-1. C) VPA increases the degree of
H2BK120 acetylation in all cell lines except THP-1 and MV4-11,
where the level of acetylation is decreased.
(PDF)
Table S1 In silico human AML gene expression screen
investigated for effects on synthetic lethality by RNAi
and VPA treatment in C. elegans.
(DOC)
Table S2 UTX-binding genes from the gene expression,
C. elegans and BNML screen.
(DOC)
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